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Nucleotide-binding domain and leucine-rich repeat containing receptors (NLRs) are intra-
cellular proteins mainly involved in pathogen recognition, inflammatory responses, and cell
death. Until recently, the function of the family member NLR caspase recruitment domain
(CARD) containing 5 (NLRC5) has been a matter of debate. It is now clear that NLRC5
acts as a transcriptional regulator of the major-histocompatibility complex class I. In this
review we detail the development of our understanding of NLRC5 function, discussing
both the accepted and the controversial aspects of NLRC5 activity. We give insight into the
molecular mechanisms, and the potential implications, of NLRC5 function in health and
disease.
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INTRODUCTION
Nucleotide-binding domain and leucine-rich repeat (LRR) con-
taining proteins (NLRs) play pivotal roles as intracellular pattern
recognition receptors (PRRs) mediating detection of invading
pathogens and triggering innate immune responses. Most NLRs
are involved in either NF-κB signaling or interleukin (IL)-1β and
IL-18 processing (1, 2). Nonetheless, functions beyond pathogen
recognition have been reported for several NLRs [reviewed in
Ref. (3)]. In mammals, NLRs are a large protein family, includ-
ing 22 members in humans (4). They have a common tripartite
structure, which consists of an N-terminal effector domain, a cen-
tral nucleotide-binding domain and a C-terminal LRR-containing
region [reviewed in Ref. (3, 5)]. The N-terminal effector domain of
NLR proteins is in most cases either a caspase recruitment domain
(CARD) or a pyrin domain that link to different signaling pathways
[reviewed in Ref. (6, 7)] (Figure 1).
In this review, we focus on the NLR CARD containing
5 (NLRC5), a recently characterized family member involved
in the regulation of major-histocompatibility complex (MHC)
class I transcription. In particular, we will discuss the current
understanding of NLRC5 expression patterns; the function of
NLRC5 in vitro and in vivo; and how NLRC5 is implicated in
immunological function and disease.
THE MHC CLASS II TRANSCRIPTIONAL ACTIVATOR: A
PARADIGM FOR NLRC5 FUNCTION
The best example of an NLR protein that does not function as
a PRR is the MHC class II transcriptional activator (CIITA).
In contrast to other NLR proteins, CIITA harbors a unique N-
terminal transcription activation domain (AD) followed by a
proline/serine/threonine-rich region (P/S/T) [reviewed in Ref.
(8)]. CIITA was originally discovered through an expression
cloning approach using an MHC class II deficient clone of the
Burkitt Lymphoma B cell line Raji (9–12). Steimle and colleagues
identified a cDNA that complemented MHC class II expression,
and termed the encoded protein CIITA (12).
Major-histocompatibility complex class II molecules are
expressed constitutively on professional antigen presenting cells
(APCs) and display antigens of exogenous origin. Phagocytosed
antigens undergo endosomal degradation and are loaded onto
MHC class II molecules in the so-called “MHC class II com-
partment.” Peptide-MHC class II complexes are then transported
to the cell surface, where foreign antigens activate CD4+ T cells
[reviewed in Ref. (13)] (Figure 2). Not surprisingly, CIITA loss of
function mutants are associated with a severe immunodeficiency
called bare lymphocyte syndrome (BLS). This condition is char-
acterized by a lack of MHC class II expression, deficiency in helper
T cells, and impaired humoral and cytotoxic responses (12).
In humans, CIITA transcription is tightly regulated and can
be induced by the differential use of four alternative promoters,
pI–pIV. However, the relevance of pII, which is used at low rate,
remains unclear and only pI, pIII, and pIV are conserved in mice
(14). Each promoter initiates transcription at unique sites, result-
ing in four isoforms of CIITA that differ in their N-terminus. pIII
is mainly used in B cells, activated human T cells, and plasma-
cytoid dendritic cells (pDCs) (8, 14). By contrast, pI is active in
DCs and results in a transcript that encodes an N-terminal CARD-
domain. This isoform is the most efficient at inducing MHC class
II expression in vitro (15), though its physiological role remains
elusive (16). Interferon (IFN)-γ leads to high induction of CIITA
expression, mainly through activation of pIV (14, 17).
In addition to CIITA, MHC class II transcription requires the
DNA-binding factors regulatory factor X (RFX) 5, RFX-AP, and
RFX-ANK (or RFX-B) (18–21). These RFX proteins specifically
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FIGURE 1 | Schematic representation of members of the mammalian
NLR-family. NLRs share a tripartite domain architecture and can be
subdivided based on the identity of their N-terminal effector domain which
links to different cellular signaling pathways. All NLRs contain a central
nucleotide-binding domain (NACHT) that mediates oligomerization. In
addition, most NLRs contain putative ligand-sensing leucine-rich repeats
(LRRs) and a variable N-terminal effector domain. The effector domain can
be a pyrin domain (PYD), a caspase recruiting domain (CARD), or a
baculovirus inhibitor of apoptosis repeat (BIR). Additional abbreviations:
FIIND, function to find; DD, death-domain different from a typical CARD
and PYD; AD, activation domain; P/S/T, proline/serine/threonine-rich protein
domain.
bind to the X1-box inside the conserved SXY motif of the MHC
class II promoters (22) (Figure 3). They assemble, together with
X2BP (23, 24) and NF-Y factors (25, 26), into a DNA-binding plat-
form known as the enhanceosome. CIITA itself does not directly
bind DNA but rather uses the enhanceosome to dock to the MHC
class II promoter to activate gene transcription by recruiting the
general transcription machinery and histone-modifying enzymes
[reviewed in Ref. (27, 28)] (Figure 3). CIITA not only governs
the transcriptional regulation of the MHC class II α-chain and
β-chain, but also regulates expression of other genes in the MHC
class II locus, including the invariant chain (li), human leukocyte
antigen (HLA)-DM, and HLA-DO. Interestingly, CIITA has also
been reported to control expression of IL-4, Fas-ligand (CD95L),
collagen A2, and some viral proteins [summarized in Ref. (29)].
By contrast to the presentation of exogenous antigens by MHC
class II molecules to CD4+ T cells, endogenous peptides are pre-
sented by MHC class I to CD8+ T cells. Differently from MHC class
II, MHC class I gene expression can be regulated by NF-κB and
IFN-sensitive response element (ISRE) binding sites located within
the promoter regions, which are absent in MHC class II promoters.
In particular the classical MHC class I molecules HLA-A and HLA-
B can be induced by NF-κB and are highly transactivated by IFN-γ
(30, 31) (Figure 3). However, transcription of MHC class I genes,
which are expressed in almost all nucleated cells, also occurs in
the absence of NF-κB or interferon regulatory factor (IRF) sig-
naling. MHC class I levels differ between tissues and cell types,
indicative of a complex regulatory network (32). Interestingly, an
SXY motif is also present in MHC class I promoter regions (33)
(Figure 3) and several groups reported an involvement of CIITA
in MHC class I expression in vitro via the enhanceosome (34–37).
However, this could not be validated in vivo, as Ciita-deficient mice
show normal MHC class I expression, suggesting the presence of
additional factors driving basal MHC class I expression through
the SXY regulatory region (38).
Intriguingly, alignment studies of the human NLR-family per-
formed for the nucleotide-binding domain and the LRR region
revealed a close homology between human CIITA and human
NLRC5, suggesting that the latter might exhibit a function analo-
gous to CIITA (39–42). Although, NLRC5 shows a typical tripartite
NLR domain organization, it should be mentioned that it contains
a rather unusual long LRRs and harbors a N-terminal effector
domain with a predicted death-domain (DD) fold different from
regular DD, DED, PYD, or CARD domains (39, 43, 44).
NLRC5 EXPRESSION AND REGULATION
Recent insights into the expression of NLRC5 have shown con-
stitutive levels in several tissues. mRNA is abundant in lymphoid
organs such as lymph nodes and spleen, and – particularly in
humans – in the lung and the intestinal tract. This implies a role
for NLRC5 in the immune response and may suggest a specific role
at mucosal surfaces (41, 43, 45). Taking a closer look at hematopoi-
etic cells, high levels of NLRC5 transcripts were observed in T and
B cells, and lower levels in CD14+ leukocytes. A detailed analysis
of NLRC5 expression at the protein level in murine tissues and
primary hematopoietic cells confirmed these observations (46).
NLRC5 is induced by several stimuli including type I and
II IFNs (41, 42, 46, 47). To better understand the transcrip-
tional regulation of NLRC5, Kuenzel and co-workers analyzed the
promoter region of the human NLRC5 gene using a bioinfor-
matic approach. They identified putative cis-elements that might
Frontiers in Immunology | Molecular Innate Immunity November 2013 | Volume 4 | Article 397 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neerincx et al. NLRC5, at the heart of antigen presentation
FIGURE 2 | Classical routes of antigen presentation by MHC class I and II
molecules. Class I antigen presentation (left-hand side): proteasomes
generate peptides from all proteins present within the cell. Peptide fragments
are transported to the endoplasmic reticulum, where they are further
trimmed by aminopeptidases and loaded onto the MHC class I molecule.
MHC class I-loaded complexes are transported to the cell surface, where they
are presented to CD8+ T cells. Class II antigen presentation (right-hand side):
extracellular antigens are taken up within phagosomes by APCs. Phagosomes
fuse with lysosomes, which contain proteolytic enzymes that cleave the
phagocytosed proteins into small peptides. Newly synthesized MHC class II
molecules from the endoplasmic reticulum are delivered to the
phagolysosomes and loaded with peptide. Peptide-loaded MHC class II
complexes are transported to the cell surface, allowing antigen presentation
to CD4+ T cells. Additional abbreviations: Ii, MHC class II-associated invariant
chain; MIIC, MHC class II compartment; TAP, transporter associated with
antigen processing.
regulate NLRC5 expression (47). These regulatory elements con-
sist of two signal transducer and activator of transcription (STAT)
consensus-binding sites at position−1336 and−452 that, accord-
ing to Genomatix, would be specific for the transcription fac-
tors STAT1 or STAT3 (48). A potential NF-κB consensus-binding
site, partially overlapping with the STAT binding site at position
−1336, was identified in the human promoter (47). Kuenzel and
co-workers showed that IFN-γ-mediated NLRC5 promoter trans-
activation was partially abrogated in the absence of either STAT
binding site. Accordingly, in different hematopoietic mouse cells
and human HeLa cells, NLRC5 expression was increased early
upon treatment with both type I and II IFNs in a STAT1-dependent
manner (42, 46). However, it is important to point out that an
ISRE binding site, which can be bound by STAT and IRF com-
plexes, has been predicted in the promoter of NLRC5 (44, 47).
Therefore, IFN-mediated NLRC5 induction could be dependent
on this additional regulatory sequence. Thus, the importance of
these predicted binding sites in NLRC5 maintenance or induction
still awaits thorough characterization.
Innate immune stimuli such as polyinosinic-polycytidylic acid
(Poly I:C) and lipopolysaccharide (LPS) efficiently induce NLRC5
expression in bone marrow-derived macrophages (BMDMs)
through the autocrine effect of type I IFNs. This was demonstrated
with the use of Ifnar- and Stat1-deficient cells (46). In addition
the use of Trif (TIR-domain-containing adapter-inducing IFN-
β)-deficient and Myd88 (myeloid differentiation primary response
gene 88)-deficient BMDMs showed that upregulation of NLRC5
by LPS was dependant on the toll-like receptor (TLR) 4 adaptor
protein Trif (46). Moreover, inflammatory stimuli such as IFN-
γ, poly I:C, or Sendai Virus (SeV), a virus inducing strong IFN
responses, also enhanced NLRC5 expression in human primary
dermal fibroblasts, the epithelial carcinoma cell line HeLa, and the
colon carcinoma cell lines CaCo2 and HT29 (43, 47).
Since several isoforms have been described for CIITA, it is con-
ceivable that NLRC5 could also possess different mRNA variants.
Indeed, six isoforms varying in their C-terminal LRR sequences
have been reported in databases (www.uniprot.org; Q86WI3).
Isoform 3, which is missing the entire LRR region, was found
to be mainly expressed in CD8+ and CD4+ lymphocytes. Iso-
forms 4 and 5, which both lack exon 25, were detected at low
levels in THP-1 cells (43). Whether these different NLRC5 isoforms
have any biological relevance remains to be established. While for
some NLRs, such as NOD1 and NOD2, the LRR region has been
involved in sensing pathogen- or danger-associated molecular pat-
terns (PAMPs or DAMPs) (49, 50), it can also have autoinhibitory
functions (1). Thus the different isoforms of NLRC5 deserve fur-
ther investigation, as they could either diversify its potential ligand
binding ability or alter its autoregulatory activity.
www.frontiersin.org November 2013 | Volume 4 | Article 397 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neerincx et al. NLRC5, at the heart of antigen presentation
NLRC5 CONTROLS BASAL MHC CLASS I GENE EXPRESSION
Given the phylogenetic proximity between CIITA and NLRC5,
Meissner and co-workers used overexpression and RNA inter-
ference (RNAi)-mediated knockdown to study the capacity of
NLRC5 to activate MHC gene transcription (42). They found that
NLRC5 overexpression induced classical MHC class I molecules in
HEK293T and in Jurkat cells. This finding has been subsequently
confirmed and extended to both primary cells and other cell lines
(42, 46, 51–56). Interestingly, human NLRC5 is able to restore
MHC class I expression in the murine melanoma cell line B16F10,
which is defective for MHC class I expression (53). NLRC5 knock-
down in THP-1 cells, poly I:C-treated Jurkat T cells, HeLa cells, and
human dermal fibroblasts confirmed that NLRC5 contributes to
MHC class I expression in these cells (42, 53). Moreover, HLA-B
and NLRC5 expression correlate in several human tissues sup-
porting the function of NLRC5 as a transactivator of MHC class
I genes (53), although discordant results from lung tissue suggests
the existence of additional control mechanisms.
Classical MHC class I molecules are highly polymorphic and
consist of a heavy chain (encoded by the genes HLA-A, -B, and
-C) and the β2-microglobulin chain. Peptide fragments presented
in MHC class I mainly derive from cytosolic proteins degraded
by the 26S proteasome which can be supported by additional
subunits forming the so-called “immunoproteasome” (57). Pep-
tides are then transported into the endoplasmic reticulum (ER) by
the peptide transporter associated with antigen processing (TAP),
in which the MHC class I molecules are present as membrane-
bound proteins stabilized by a subset of chaperones. Following
further aminopeptidase-mediated cleavage, peptides are loaded
onto the MHC class I molecule by the peptide-loading com-
plex, which includes TAP1, TAP2, and tapasin. Antigen-loaded
MHC class I molecules are transported via the Golgi-network
to the cell surface, where they are detected by specific recep-
tors on CD8+ T cells, as depicted in Figure 2 [reviewed in Ref.
(13)]. Interestingly, NLRC5 also controls the expression of MHC
class I-related genes, such as β2-microglobulin, TAP1, and the
immunoproteasome subunit low molecular mass poylpeptides 2
(LMP2) (42).
The forced expression of NLRC5 also leads to induction of
the non-classical MHC class I genes HLA-E, F, G, less poly-
morphic molecules that are mainly involved in Natural Killer
(NK) cell inhibition (42). Altogether, these data indicate NLRC5
FIGURE 3 | Major-histocompatibility complex class I and II promoters.
MHC class I gene regulation (upper panel). Expression of MHC class I
genes is regulated by several elements in the promoter region. For
instance, the enhancer A sequence allows binding of the transcription
factor NF-κB; the interferon stimulated response element (ISRE) serves as
an active site for interferon regulator factor 1 (IRF1). In addition, a
conserved SXY module is found in the proximal MHC class I gene
promoters. MHC class II gene regulation (lower panel). The MHC class II
gene contains an SXY module that facilitates assembly of the so-called
enhanceosome. The enhanceosome is a protein complex containing
regulatory factor X (RFX) proteins, cAMP response element-binding
protein (CREB), and the nuclear factors Y (NF-Y). The assembly of this
protein complex constitutes a platform for the recruitment the class II
transactivator CIITA. Additional abbreviation: RFX-AP, RFX-associated
protein; RFX-ANK, RFX-associated ankyrin-containing protein; TFs,
transcription factors.
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to be a key player in the process of MHC class I-mediated
antigen presentation.
MOLECULAR ASPECTS OF NLRC5 TRANSCRIPTIONAL
REGULATORY FUNCTION
NLRC5 TRANSCRIPTIONAL REGULATORY ACTIVITY DEPENDS ON THE
ENHANCEOSOME
As discussed above, CIITA-dependent MHC class II activation
requires the enhanceosome complex, which binds to the SXY
motif of the MHC class II promoter region [reviewed in Ref. (8,
27)]. A similar region in the MHC class I promoter was shown
to be important for enhanceosome-dependent MHC class I acti-
vation (36) (Figure 3). Importantly, NLRC5 has been shown
to occupy the promoter of MHC class I genes in the region
encompassing the SXY module by chromatin immunoprecipi-
tation assays (42, 46). Mutation of the X1- and X2-motifs, as
well as the absence of selected enhanceosome components, abol-
ished NLRC5-dependent MHC class I activation, demonstrat-
ing that NLRC5-mediated MHC class I activation is dependent
on components of the enhanceosome (53, 58). Consistent with
this, ankyrin repeat dependent interaction of RFX-ANK and
NLRC5 has been reported (58). In addition, Meissner and col-
leagues identified the S-motif as important for NLRC5-dependent,
but not CIITA-dependent, transactivation (Figure 3) (58). The
S-motif has been implicated in enhanceosome-dependent reg-
ulation of MHC transcription (59). However, its precise role
in NLRC5-dependent gene regulation still needs to be estab-
lished.
Altogether, these results reveal that NLRC5 exerts transcrip-
tional regulation in an enhanceosome-dependent manner. A
future challenge is to understand the epigenetic mechanisms
underlying NLRC5-dependent transactivation of MHC class I
gene promoters; the first insights into this important aspect are
just starting to emerge, as recently reviewed (44).
MOLECULAR MECHANISMS OF NLRC5 NUCLEAR LOCALIZATION
The transcriptional function of NLRC5 requires an ability to shut-
tle into the nucleus. NLRC5 strongly accumulates in the nucleus
upon inhibition of nuclear export, while at steady-state condi-
tions only a minor portion is detectable within the nucleus (41,
42, 46, 47, 53). In contrast, CIITA is evenly distributed between
cytoplasm and nucleus (60, 61). An N-terminally located nuclear
localization sequence (NLS) is responsible for the nuclear shut-
tling of NLRC5 (42, 52, 53). However, this process is also reported
to depend on the Walker A motif that constitutes the nucleotide-
binding site of the central nucleoside triphosphatase (NTPase)
domain (see Figure 1) (52, 53). Of note, disruption of the Walker
A box in CIITA was also shown to diminish MHC transactiva-
tion and nuclear shuttling (62, 63). However, these results should
be interpreted cautiously, as mutation of the Walker A site might
affect overall protein structure.
NLRC5 and CIITA show close sequence homology in their LRR
regions (40). However, the LRR regions differentially affect their
subcellular localization. For CIITA it has been shown that several
structural features of the LRRs are important for nuclear import
(60, 61, 64). In contrast the LRR region of NLRC5 is dispens-
able for nuclear import, but appears to be involved in nuclear
export. NLRC5 constructs lacking the LRR region showed nuclear
localization even in the absence of blockage of nuclear export
(52, 53).
Paradoxically, forced nuclear localization of NLRC5 (by fusion
of a strong viral NLS) results in reduced MHC class I transactiva-
tion potential (52, 53). This could mean that the transcriptional
activity of NLRC5 might depend on cytoplasmic modifications
that cannot be carried out correctly if the protein only resides
briefly in the cytoplasm. Of note, NLRC5 runs as a double band in
SDS-gel electrophoresis, which might be indicative of such a post-
translational modification,although its nature remains to be estab-
lished (46, 47). Alternatively, enhanced nuclear import of NLRC5
might interfere with the formation of NLRC5 protein–protein
complexes in the cytosol that confer transcriptional activity upon
translocation to the nucleus.
HINTS FROM NLRC5-ANALOGOUS PROTEINS IN MAMMALIAN AND
PLANT CELLS
As discussed above, our understanding is that NLRC5, similarly to
CIITA, is active without any DAMP or PAMP stimulus; its activity
relying mainly on the expression level. This is in sharp contrast
with the current idea of NLR activation, in which a DAMP or
PAMP is needed to induce a conformational change and activate
these proteins. It remains to be established if the LRRs of NLRC5
have PAMP or DAMP binding capacity that might further regu-
late activity. However, in the case of both NOD1 and NOD2, for
which a clear activator has been defined, high expression levels are
sufficient to confer autoactivation (65).
Although it has been presumed that plants and animals use
different immune mechanisms to detect pathogens, there are
interesting studies showing remarkable similarities in the struc-
ture and function of the receptors that recognize microbial anti-
gens [reviewed by Ronald and Beutler (66)]. In fact, plants har-
bor Nucleotide-Binding-Leucine-Rich Repeat (NB-LRR) proteins,
which have a similar structure to NLRs and also function as intra-
cellular PRRs to ensure immunity against invading pathogens.
Many of these NB-LRR proteins are present both in the cytoplasm
and nucleus and function as transcriptional regulators [reviewed
by Padmanabhan and Dinesh-Kumar (67)]. Recently, it was shown
that two plant NB-LRR proteins [Barley mildew A (MLA) and
Nicotiana tabacum TIR-NB-LRR immune receptor N] enhance
pathogen-mediated defense gene transcription by forming a com-
plex with specific plant transcription factors (68, 69). The similar
function of CIITA and NLRC5 to these plant proteins makes it
tempting to speculate that convergent evolution might also have
selected similar regulatory mechanism (70).
IN VIVO NLRC5 FUNCTION AND RELEVANCE IN HEALTH AND
DISEASE
LESSONS FROM KNOCKOUT MOUSE MODELS
The involvement of NLRC5 in MHC class I regulation was con-
firmed in Nlrc5-deficient mice by several independent studies
(46, 51, 54–56). These works also enabled to determine the
contribution of NLRC5 to MHC class I expression in differ-
ent cell types. The greatest decrease in MHC class I expres-
sion was observed in CD4+ and CD8+ T cells, NK, and NKT
cells; a significant defect was seen in B cells; and a more
www.frontiersin.org November 2013 | Volume 4 | Article 397 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neerincx et al. NLRC5, at the heart of antigen presentation
moderate defect in DCs and macrophages (46, 51, 54). The
most prominent lack of MHC class I expression was therefore
noticed among immune cells, where NLRC5 is mainly expressed
at the steady-state (43, 46). However, analysis of MHC class I
expression in thymic epithelial cells (TECs), revealed that Nlrc5-
deficiency decreased their MHC class I display (46), indicat-
ing that NLRC5 also participates in MHC class I expression
in non-hematopoietic tissues; a function that deserves further
investigation.
Major-histocompatibility complex class I is not only the key
molecule for CD8+ T cell activation and function but is also
essential for thymic selection and peripheral maintenance of naïve
CD8+ T cells. In line with that, two reports detected slightly
reduced total CD8+ T cell levels in the spleen of Nlrc5-deficient
mice under steady-state conditions (46, 56). This strongly suggests
that the diminished MHC class I levels encountered in knock-
out animals affects CD8+ T cell homeostasis. In addition, the
decreased surface MHC class I levels described above in Nlrc5-
deficient TECs suggests that Nlrc5-deficiency might alter thymic
selection and – potentially – the TCR repertoire.
The use of knockout animals also highlighted the ability of
Nlrc5-deficient cells to increase their surface MHC class I levels
following treatment with inflammatory stimuli such as IFNs or
LPS, both in T cells and macrophages (46, 51, 54). In fact, although
the defect in MHC class I expression observed in Nlrc5-deficient
cells was maintained after stimulation, both control and knockout
cells were able to substantially augment their MHC class I levels.
This reiterates the existence of Nlrc5-independent mechanisms
that regulate MHC class I (Figure 3).
NLRC5 IN INFECTIONS
Given the recent discovery of NLRC5, we have just started to gain
insight into the significance of this NLR in pathological condi-
tions. Based on current knowledge one would have predicted it to
be important in viral infections. However, the only information to
date on the effects of Nlrc5-deficiency in this context come from
an acute model of VSV viral infection in which no significant dif-
ferences were observed between control and knockout mice (55).
It would be extremely valuable to assess the ability of knockout
animals to control less acute viral infections in which the adaptive
immune response is activated.
Nonetheless, two studies clearly show that NLRC5 is important
in the control of infection by Listeria monocytogenes, a Gram-
positive motile bacterium that primarily infects monocytes and
macrophages. One week post-inoculation, Nlrc5-deficient mice
showed severely reduced numbers of IFN-γ-producing CD8+ T
cells (51, 56). In agreement with this observation, bacterial clear-
ance was affected and an increased bacterial burden observed in the
liver and spleen of knockout animals. Surprisingly, the difference
in restriction of L. monocytogenes infection was observed as early
as 1 day after infection, indicating that besides the impaired CD8+
T cell-mediated response, an early defect in the innate response
occurs in the absence of NLRC5 (56). The authors explained this
by the observation of a partial defect in IL-1β production in Nlrc5-
deficient mice upon infection. Future work aimed at dissecting the
contribution of NLRC5 to the innate and the adaptive responses
will be extremely important.
NLRC5 AND TUMOR SURVEILLANCE
Because MHC class I surface expression was strongly diminished
among Nlrc5-deficient lymphoid cells, the efficiency of CTLs in
killing these cells was evaluated. In agreement with their reduced
ability to present antigen, Nlrc5-deficient target T cells were elim-
inated less than control T cells by cognate CTLs in vitro (46).
Although this observation still awaits confirmation in vivo, it
has long been known that several malignancies, and in partic-
ular, hematological tumors, often lose MHC class I expression.
This may enable more efficient evasion of immunosurveillance
mechanisms. Mutations or epigenetic silencing that mostly target
β2M or single HLA genes have been identified in these tumors
(71). As such, NLRC5 mutation or silencing that results in down-
regulation of classical MHC class I in lymphoid malignancies
could favor tumor development. Interestingly, the screening of
a handful of lymphoid tumor cell lines suggested that NLRC5
is indeed expressed at low levels in several of these. In any case,
NLRC5 expression level strongly correlates with the expression
of a number of MHC class I genes in human tumor cell lines
(Broad-Novartis Cancer Cell Line Encyclopedia). Future studies
aimed at evaluating NLRC5 expression and mutations in a larger
number of lymphoid tumor cells, and in primary tumors will
contribute to delineate the potential importance of NLRC5 in
tumor progression.
Displaying reduced MHC class I expression to escape CTL-
mediated immunosurveillance can result in increased NK cell-
mediated lysis. In fact, NK cells kill cells lacking the expression of
MHC class I molecules, according to the “missing-self” hypothesis
(72). For now studies addressing the role of NLRC5 in NK cell
biology have yet to be performed.
EMERGING FUNCTIONS OF NLRC5 IN ANTIVIRAL AND
INFLAMMATORY RESPONSES
The first characterization of NLRC5 showed that it can activate
ISRE- and IFN-γ activating sequence (GAS)-containing promot-
ers in human HeLaS3 cells (47). However, NLRC5 overexpression
in other human cell lines failed to strongly activate important pro-
inflammatory pathways such as NF-κB, mitogen-activated protein
kinase (MAPK) or type I IFN (41, 43). Several studies reported that
that overexpression of human NLRC5 actually resulted in an inhi-
bition of NF-κB, activator protein 1 (AP1), and ISRE signaling; as
well as TANK-binding kinase 1 (TBK1)- and SeV-mediated IFN-β
promoter activation in HEK293T cells (41, 43, 45). The ability of
NLRC5 to bind components of the NFκB and type I IFN path-
way, namely IκB kinase (IKK)-α, IKK-β, retinoic acid-inducible
gene 1 (RIG-I), and melanoma differentiation-associated protein
5 (MDA5) (45), led to the suggestion that NLRC5 overexpression
interfered with these factors to inhibit inflammatory signaling. In
spite of this, two independent studies using RNAi, revealed that
human NLRC5 positively contributes to type I IFN expression
upon viral infection in human cells (47, 53). This observation
contrasts with the results of NLRC5 overexpression in HEK293T
cells and highlights the difficulty in interpreting functional studies
based on NLR overexpression (73).
In cells from Nlrc5 knockout mice, PRR-mediated IFN and
NF-κB signaling were also shown to be affected in embryonic
fibroblasts, peritoneal macrophages, and – to a lesser extent – in
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BMDMs (55). However, no differences were observed in BMDMs
and dendritic cells in complementary studies using three indepen-
dently generated Nlrc5 knockout mouse strains (46, 54, 74). In par-
ticular, work by Kumar and colleagues clearly showed that myeloid
cells derived from Nlrc5-deficient mice showed no significant
changes in the production of IFN-β or IL-6 after treatment with
RNA viruses, DNA viruses, and bacteria (74). Moreover, serum
IFN-β, IL-6, and IL-1β levels after polyI:C injection were also
comparable between control and knockout mice. This discrepancy
remains to be addressed by future works.
Many NLRs form multimeric complexes called inflamma-
somes that act as scaffold for the activation of the inflammatory
caspase-1, which in turn cleaves and hence activates IL-1β and
IL-18 (1). Several reports show that NLRC5 is able to enhance
inflammasome-mediated IL-1β processing in human and murine
cells. In human HEK293T cells ectopically expressing pro-IL-1β
and pro-caspase-1, NLRC5 expression led to dose dependent IL-1β
release (74). In isolated murine macrophages and dendritic cells
derived from Nlrc5-deficient animals, activation of the NLRP3 and
Aim-2 inflammasome was normal, although Francisella tularensis-
mediated IL-1β release, that depends on Aim-2, might be affected
(74). Also in human myeloid THP-1 cells, bacterial- and PAMP-
induced IL-1β secretion, but not pore forming toxin-dependent
activation of the inflammasome, was reduced upon silencing of
NLRC5 expression (75). This was suggested to be mediated by
interactions of NLRC5 with NLRP3 and the inflammasome adap-
tor protein ASC (56, 75). Despite the reported discrepancies,
the observed effects of NLRC5 expression on the inflammasome
and, more precisely, on NLRP3-specific stimuli deserve further
research.
Taken together, NLRC5 appears to have distinct functions
depending on its cytoplasmic or nuclear location (Figure 4). In
FIGURE 4 | Described functions of NLRC5. Both type I and II IFNs strongly
induce NLRC5 expression through STAT1 activation. NLRC5 can then shuttle
into the nucleus and bind to the enhanceosome on MHC class I gene
promoters, resulting in their expression. NLRC5 has also been shown to act
as a modifier of NF-κB activity and type I interferon responses induced by
PRRs recognizing microbial nucleic acids. Additional abbreviation: IRF,
interferon regulator factor; ISRE, interferon stimulated response element;
CREB, cAMP response element-binding protein; IKK, IκB kinase complex;
IKKε, IκB kinase subunit epsilon; NF-Y, nuclear factor Y; RFX5, regulatory factor
X 5; RFX-AP, RFX-associated protein; RFX-ANK, RFX-associated
ankyrin-containing protein; RLRs, RIG-I-like receptors; TBK1, TANK-binding
kinase 1; TFs, transcription factors; TLRs, toll-like receptors.
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the cytoplasm NLRC5 might influence canonical innate immune
pathways, including type I IFN signaling and NF-κB signaling;
at least in some cell types and species (41, 43, 45, 47). On
the other hand, nuclear NLRC5 is a master regulator of MHC
class I gene expression both in human and murine cells (42,
46, 53, 55, 56, 58). Additional studies are needed to elucidate
the detailed cytoplasmic function of NLRC5, particularly with
regard to the potential functional differences between humans
and mice.
CONCLUDING REMARKS
A substantial amount of evidence supports NLRC5 as the long
sought after transcriptional regulator of MHC class I in human
and murine cells, particularly in the hematopoietic lineage. How-
ever, emerging evidence suggests additional roles for this NLR in
innate immune responses; roles we are only starting to understand
and which require further investigation. We are beginning to gain
insight into the molecular mechanisms underlying the transcrip-
tional regulatory function and physiological relevance of NLRC5.
In spite of the little understanding we have to date of NLRC5-
mediated activities, its role as transcriptional regulator of MHC
class I anticipates that important functions in health and disease
await discovery.
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